According to Nasdaq’s data, the U.S. saw 179 non-SPAC IPOs in 2024 – the most since 2021, and a 40% increase over 2023 (127). By value raised (ex SPACs), it was an even better year, with value raised ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Impinj has shown impressive revenue growth post-2020 but has faced persistent operating losses since its 2016 IPO. The ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After a two-and-a-half-year lull in SPAC activity, the second half of 2024 brought glimmers of sunshine to the otherwise ...

Rubrik’s RBRK shares have rallied 90% since its initial public offering on April 25, outperforming the Zacks Computer & ...

Is the GYG valuation too spicy? The post Guzman Y Gomez shares: Overvalued or still a buy? appeared first on The Motley Fool ...

The Bay Area-based biotech revealed the planned IPO in a Jan. 7 filing with the Securities and Exchange Commission but did not divulge how many shares it plans to offer nor at what price.